| Primary |
| Neuroleptic Malignant Syndrome |
24.0% |
| Product Used For Unknown Indication |
10.2% |
| Muscle Spasticity |
7.5% |
| Constipation |
6.3% |
| Renal Failure Chronic |
6.3% |
| Insomnia |
4.7% |
| Muscle Spasms |
4.7% |
| Osteoarthritis |
4.3% |
| Hypertension |
3.9% |
| Cerebral Palsy |
3.5% |
| Pruritus |
3.1% |
| Pneumonia |
2.8% |
| Spinal Ligament Ossification |
2.8% |
| Cerebrovascular Spasm |
2.4% |
| Diabetes Mellitus |
2.4% |
| Eczema Asteatotic |
2.4% |
| Nephrogenic Anaemia |
2.4% |
| Schizophrenia |
2.4% |
| Epilepsy |
2.0% |
| Hypercholesterolaemia |
2.0% |
|
| Vomiting |
10.7% |
| Urinary Tract Infection |
8.3% |
| Inappropriate Antidiuretic Hormone Secretion |
7.1% |
| Off Label Use |
7.1% |
| Drug Ineffective |
6.0% |
| Condition Aggravated |
4.8% |
| Dysphagia |
4.8% |
| Infusion Site Irritation |
4.8% |
| Pneumonia |
4.8% |
| Pyrexia |
4.8% |
| Rhabdomyolysis |
4.8% |
| Altered State Of Consciousness |
3.6% |
| Bradycardia |
3.6% |
| Cardio-respiratory Arrest |
3.6% |
| Drug Ineffective For Unapproved Indication |
3.6% |
| Hyponatraemia |
3.6% |
| Platelet Count Decreased |
3.6% |
| Pneumonia Aspiration |
3.6% |
| Respiratory Failure |
3.6% |
| Toxic Skin Eruption |
3.6% |
|
| Secondary |
| Neuroleptic Malignant Syndrome |
12.9% |
| Insomnia |
11.6% |
| Product Used For Unknown Indication |
10.8% |
| Asthma |
8.8% |
| Epilepsy |
6.7% |
| Relapsing-remitting Multiple Sclerosis |
6.2% |
| Drug Therapy |
5.2% |
| Constipation |
4.9% |
| Drug Use For Unknown Indication |
4.4% |
| Bronchitis Chronic |
3.1% |
| Schizophrenia |
3.1% |
| Bronchitis |
2.6% |
| Gastric Haemorrhage |
2.6% |
| Hypertension |
2.6% |
| Muscle Spasticity |
2.6% |
| Muscle Tightness |
2.6% |
| Parkinsonism |
2.6% |
| Spinal Ligament Ossification |
2.6% |
| Hypotonia |
2.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.1% |
|
| Drug Ineffective |
13.4% |
| Dysphagia |
9.8% |
| Off Label Use |
9.8% |
| Acne |
8.5% |
| Gastrointestinal Haemorrhage |
6.1% |
| Syncope |
6.1% |
| Condition Aggravated |
4.9% |
| Laryngeal Oedema |
4.9% |
| Pyrexia |
4.9% |
| Thrombocytopenia |
4.9% |
| Muscle Spasms |
3.7% |
| Protein Urine Present |
3.7% |
| Altered State Of Consciousness |
2.4% |
| Eye Movement Disorder |
2.4% |
| Fracture |
2.4% |
| Gamma-glutamyltransferase Increased |
2.4% |
| Hamartoma |
2.4% |
| Hepatitis Fulminant |
2.4% |
| Hypothermia |
2.4% |
| Jaundice |
2.4% |
|
| Concomitant |
| Multiple Sclerosis |
10.0% |
| Product Used For Unknown Indication |
8.0% |
| Renal Transplant |
7.6% |
| Muscle Spasticity |
6.5% |
| Sedative Therapy |
6.1% |
| Drug Use For Unknown Indication |
6.0% |
| Epilepsy |
5.6% |
| Prophylaxis |
4.9% |
| Insomnia |
4.6% |
| Schizophrenia |
4.4% |
| Pain |
4.2% |
| Muscle Spasms |
4.1% |
| Depression |
3.9% |
| Diarrhoea |
3.9% |
| Torticollis |
3.9% |
| Hypertension |
3.7% |
| Cerebral Palsy |
3.3% |
| Thrombosis Prophylaxis |
3.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.0% |
| Relapsing-remitting Multiple Sclerosis |
3.0% |
|
| Neuroleptic Malignant Syndrome |
13.6% |
| Urinary Tract Infection |
6.8% |
| Vomiting |
6.8% |
| Somnolence |
5.8% |
| Urine Output Decreased |
5.8% |
| Urine Output Increased |
5.8% |
| White Blood Cell Count Decreased |
5.8% |
| Pneumonia |
4.9% |
| Bronchitis |
3.9% |
| Cerebrovascular Accident |
3.9% |
| Confusional State |
3.9% |
| Epilepsy |
3.9% |
| Hyperkalaemia |
3.9% |
| Hypertension |
3.9% |
| Implant Site Effusion |
3.9% |
| Multiple Sclerosis Relapse |
3.9% |
| Pancreatitis Acute |
3.9% |
| Psychiatric Decompensation |
3.9% |
| Drug Ineffective |
2.9% |
| Malaise |
2.9% |
|
| Interacting |
| Carotid Artery Occlusion |
50.0% |
| Hyperlipidaemia |
50.0% |
|
| Muscular Weakness |
66.7% |
| Liver Function Test Abnormal |
33.3% |
|
